From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver Pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and business process infrastructure for market access and therapy commercialization.
Solutions overview
IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, Market Access experts, analysts, technologies, and advisory professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Delivering Pharma’s only comprehensive data, consulting, and business process platform for market access
From helping emerging companies plan and execute their first-time launch, to supporting more than 65% of the Top 50 largest manufacturers, IntegriChain’s solutions have helped manufacturers unify market access teams and solve complex market access business challenges.
Through IntegriChain’s ICyte platform, historically siloed Market Access functions – commercial teams focused on payers and patient access; operational teams focused on contract management and pricing; and finance teams focused on gross-to-net forecasting and accruals – are able to come together through shared data, eliminating manual processes and disparate system that often hold these teams back from innovating and transforming access to their therapies.
Solutions for Finance Teams
Solutions for Operational Teams
Solutions for Market Access and Commercial Teams
From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver Pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and business process infrastructure for market access and therapy commercialization
Helping to solve claims-driven revenue leakage, Medicaid CLD Is an add-on module to IntegriChain’s rebate management service that performs detailed validation of Medicaid claims, improving the ability to detect and reject invalid claims and eliminating over-payments and/or incorrect payments associated with the claims.
Learn More
IntegriChain subject matter experts discuss the current status of drug pricing transparency laws that have been recently introduced and updated at the state level. Topics include disclosures themes, types of reports, and new reporting updates for nearly a dozen states. Watch THE WEBINAR
As the GTN bubble grows, so does increased stakeholder scrutiny on GTN analytics. Although the industry is moving toward automation, many life sciences manufacturers are currently analyzing their options, the value automation brings to the organization, and making a business case to management. READ Paper
